Paul Sakuma, Associated Press
SALT LAKE CITY — Utah will get $8.5 million from GlaxoSmithKline for defrauding the state’s Medicaid program through allegedly false and misleading marketing of Avandia.
GSK introduced Avandia in 1999 as a new diabetic medication to treat Type 2 diabetes by helping sensitize cells to insulin and thereby assisting in blood-sugar control.
The Medicaid Fraud Control Unit of the attorney general’s office filed the lawsuit in 2010 and alleged GSK marketed Avandia nationwide as a “wonder drug” and as a “significant advance” in diabetes treatment.
The lawsuit also alleged Avandia has been proven to increase the risk of cardiovascular events, including heart attacks, among certain users of Avandia.
“This settlement is a great outcome in a complex case,” said Robert Steed, director of the Medicaid fraud unit.
— Dennis Romboy
- 9 things I wish I had known before my mission
- Woman dies, husband critically injured in...
- Sandy officer shoots, critically injures man...
- The truth about addiction
- Chaffetz expected to announce he's running...
- Missing 18-month-old Layton boy found...
- Heavy rain damages roads, floods basements in...
- Small group of Ordain Women supporters gather...
- Hatch calls shutting down government... 67
- Chaffetz expected to announce he's... 49
- Federal judge halts Herbert directive... 39
- New Medicaid expansion plan unveiled to... 27
- Is convicted killer innocent? Group... 24
- Gun control laws won't stop mass... 22
- Herbert, other governors slam federal... 20
- Woman said she felt protected in ordeal... 19